TP53 has a relatively low mutation rate in some cancer types, such as thymoma (THYM) (3.3%); kidney renal papillary-cell carcinoma (KIRP) (2.5%); kidney renal clear-cell carcinoma (KIRC) (2.4%); testicular germ-cell tumors (TGCT) (1.4%); thyroid carcinoma (THCA) (0.8%); pheochromocytoma and paraganglioma (PCPG) (0.6%); and uveal melanoma (UVM) (0%). This evidence concerns the gene TP53 and thymoma.